Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

​​​​​Thermo Fisher Scientific Inc (NYSE: TMO) said that its COVID-19 diagnostic tests can accurately detect the new coronavirus variant Omicron. The Omicron variant has more than 30 mutations in the spike protein alone.

Thermo Fisher Says Its COVID-19 Tests Can Detect Omicron Variant

WALTHAM, Mass., Nov. 29, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit*, and TaqPath COVID-19 CE-IVD RT-PCR Kit*, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

Thermo Fisher's (TMO) new manufacturing facility will help the United States meet demand surges for vital laboratory products.

Thermo Fisher (TMO) New Facility to Advance Lab Products Supply

WALTHAM, Mass., Nov. 18, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it is giving notice of its intention to redeem the following Senior Notes (the "Redemption"), representing an aggregate total principal amount of approximately $2.2 billion, on December 3, 2021 (the "Redemption Date"): $1.1 billion aggregate principal amount of 4.133% Senior Notes due 2025 (the "2025 Notes"); and $1.1 billion aggregate principal amount of 4.497% Senior Notes due 2030 (the "2030 Notes" and, together with the 2025 Notes, the "Notes").

Thermo Fisher Scientific Announces Redemption of Senior Notes

The pandemic has been a tailwind for several sectors of the economy, including healthcare. One name that has especially benefited has been Thermo Fischer Scientific Inc. ( TMO , Financial).

Why Thermo Fischer Appears Undervalued

TMO has been growing at a solid pace (5 year average of 15.1%), as the health care industry and scientific research field just keeps getting bigger every day. Acquisition of contract research organization PPD will establish TMO as a leader in the rapidly growing clinical research industry and further fuel TMO's growth.

Thermo Fisher: Impressive Growth Story Just Got Better

Costco

If you want to beat the S&P 500, a good place to start is with stocks that are proven winners. Here are two.

2 Unstoppable Stocks You Can Buy and Forget About

ConocoPhillips

Disney

Home Depot

Johnson & Johnson

Procter & Gamble

UnitedHealth Group

As we move through the fourth quarter, these top defensive stocks look great for portfolio stability and consistent returns long term. The post 7 Defensive Stocks To Add Portfolio Stability in the Fourth Quarter appeared first on InvestorPlace.

7 Defensive Stocks To Add Portfolio Stability in the Fourth Quarter

Amazon

Salesforce

Alphabet

Microsoft

Stocks with market values of at least $200 billion are where the really big money places its bets. These mega caps are Wall Street's favorites.

5 Mega-Cap Stocks Analysts Love the Most

EU antitrust regulators will decide by Dec. 7 whether to clear U.S. medical device company Thermo Fisher Scientific's $21 billion bid for contract research firm PPD Inc, a European Commission filing showed on Wednesday.

EU antitrust decision on Thermo Fisher's PPD deal due by Dec. 7

PHILADELPHIA, Nov. 1, 2021 /PRNewswire/ --  ASMS 2021 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is empowering scientists to drive groundbreaking discoveries with the introduction of new-generation mass spectrometry instruments, workflows and software. The company will showcase new additions to its industry-leading offering during the 69th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held October 31-November 4, in the Pennsylvania Convention Center, Philadelphia, Pennsylvania.

Thermo Fisher Scientific Launches New Mass Spectrometry and Chromatography Solutions at ASMS 2021

Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Thermo Fisher (TMO) Hits Fresh High: Is There Still Room to Run?

Is (TMO) Outperforming Other Medical Stocks This Year?

Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?

Thermo Fisher Scientific Inc. (TMO) CEO Marc Casper on Q3 2021 Results - Earnings Call Transcript

Thermo Fisher (TMO) delivers a strong quarterly performance, leveraging on a significant rebound in its base business.

Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View

Thermo Fisher Scientific Inc (NYSE: TMO) has posted Q3 revenues of $9.33 billion, up 9% Y/Y, beating the consensus of $8.39 billion. Organic revenue growth from the base business was 10%.

Thermo Fisher's COVID-19 Response Revenue Accounts For 22% In Q3 Sales, Boosts FY21 Outlook

Thermo Fisher (TMO) delivered earnings and revenue surprises of 23.34% and 11.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Beat Estimates

Thermo Fisher Scientific (NYSE:TMO) reported its Q3 earnings results on Wednesday, October 27, 2021 at 06:00 AM. Here's what investors need to know about the announcement.

Thermo Fisher Scientific: Q3 Earnings Insights

(Reuters) -Thermo Fisher Scientific Inc raised its full-year forecast and beat third-quarter profit estimates on strength in its life sciences unit, which makes raw materials for COVID-19 vaccines, and strong performance in its laboratory product segment.

Thermo Fisher lifts full-year forecast after third-quarter profit beat

WALTHAM, Mass., Oct. 27, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended October 2, 2021.

Thermo Fisher Scientific Reports Third Quarter 2021 Results

Thermo Fisher Scientific Inc's third-quarter profit is likely to get a boost from a rebound in COVID-19 testing due to the highly contagious Delta variant and sustained demand for vaccines against the coronavirus, Wall Street analysts said.

Thermo Fisher set to benefit from demand for testing kits, vaccines

Aflac

Capital One

DexCom

Exxon Mobil

Five big S&P 500 companies (market capital > $45 billion) are slated to release third-quarter earnings results this week. These are: COF, DXCM, XOM, AFL and TMO.

5 S&P 500 Stocks to Buy Ahead of Q3 Earnings This Week

Align Technology

Boston Scientific

Edwards Lifesciences

With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.

Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More

WALTHAM, Mass., Oct. 26, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today published its 2020 Corporate Social Responsibility (CSR) report, reflecting its commitment to society, stakeholders and environmental, social and governance (ESG) efforts.

News for Thermo Fisher Scientific Stock (TMO)